Godavari Drugs Board of Directors

Get the latest insights into the leadership at Godavari Drugs. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Venkatesh AchantaCompany Secretary & Compliance Officer
Ghanshyam JajuChairman
Mukund KakaniManaging Director
Mohit JajuWhole Time Director & CFO
Dinesh UdpaNon Executive Independent Director
Shilpa BungNon Executive Independent Director
Mahendra Uday BhaleraoNon Executive Independent Director

Godavari Drugs Share price

GODAVARI

119.24

0.81 (-0.67%)
Last updated on 23 Apr, 2026 | 15:20 IST
Today's High

120.40

Today's Low

118.00

52 Week Low

69.70

52 Week High

129.85

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Godavari Drugs FAQs

The board at Godavari Drugs consists of experienced professionals, including Venkatesh Achanta, Ghanshyam Jaju, and others, overseeing the company’s strategic and corporate governance.

Directors at Godavari Drugs are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Venkatesh Achanta is the current chairman at Godavari Drugs.

Executive directors at Godavari Drugs are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Godavari Drugs adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Godavari Drugs, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost